Rocket Pharmaceuticals Inc expected to post a loss of 79 cents a share - Earnings Preview

Rocket Pharmaceuticals

23/02/2024 11:23

* Rocket Pharmaceuticals Inc  RCKT.OQ   RCKT.O  is expected
to show no change in quarterly revenue when it reports 
results on February 26 (estimated) for the period ending
December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Rocket Pharmaceuticals
Inc is
for a loss of 79 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 14 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Rocket
Pharmaceuticals Inc is $49.50​, above​ its last closing price
of $29.00. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.78       -0.81      -0.75     Beat    7.2
 Jun. 30 2023  -0.79       -0.79      -0.82     Missed  -3.8
 Mar. 31 2023  -0.86       -0.85      -0.73     Beat    14.3​
 Dec. 31 2022  -0.79       -0.80      -0.92     Missed  -14.6
 ​​Sep.        -0.80       -0.79      -0.87     Missed  -10.2
 30 2022                                                
 Jun. 30 2022  -0.66       -0.68      -0.83     Missed  -21.6​
 Mar. 31 2022  -0.72       -0.71      -0.67     Beat    5.6
 Dec. 31 2021  -0.76       -0.76      -0.69     Beat    9.6
 This summary was machine generated February 23 at 11:23 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)